1152P - Amrubicin monotherapy in patients with platinum-refractory metastatic neuroendocrine carcinoma and mixed adenoneuroendocrine carcinoma of the gastr...

Date 27 September 2014
Event ESMO 2014
Session Poster Display session
Topics Cytotoxic agents
Neuroendocrine Cancers
Therapy
Biological therapy
Presenter Tomonori Araki
Citation Annals of Oncology (2014) 25 (suppl_4): iv394-iv405. 10.1093/annonc/mdu345
Authors T. Araki1, T. Hamaguchi2, A. Takashima3, Y. Honma4, S. Iwasa4, N. Okita2, K. Kato5, Y. Yamada6, H. Hashimoto7, H. Taniguchi8, R. Kushima9, K. Nakao10, Y. Shimada11
  • 1Internal Medicine, National Hospital Organization Saga Hospital, 8498577 - Saga/JP
  • 2Gastrointestinal Oncology, National Cancer Center Hospital, JP-104-0045 - Tokyo/JP
  • 3Japan Clinical Oncology Group Data Center, Multi-institutional Clinical Trial Support Center, National Cancer Center, Tokyo/JP
  • 4Gastrointestinal Oncolgoy, national cancer center hospital, Tokyo/JP
  • 5Gastrointestinal Oncology, National Cancer Center Hospital, 104-0045 - Tokyo/JP
  • 6Medical Oncology, National Cancer Center Hospital, JP-104-0045 - Tokyo/JP
  • 7Pharmacy, National Cancer Cneter Hospital, 104-0045 - Tokyo/JP
  • 8Division Of Pathology, National Cancer Center Hospital, 104-0045 - Tokyo/JP
  • 9Division Of Pathology, National Cancer Center Hospital, JP-104-0045 - Tokyo/JP
  • 10Department Of Gastroenterology And Hepatology, Graduate School Of Biomedical Sciences, Nagasaki University, Nagasaki/JP
  • 11Gastrointestinal Oncolgoy, National Cancer Center Hospital, Tokyo/JP

Abstract

Aim

We conducted a retrospective anaysis to investigate the efficacy and safety of Amrubicin (AMR) in patients with platinum-refractory metastatic neuroendocrine carcinoma and mixed neuroendocrine carcinoma of the gastrointestinal tract (GIT-NEC/MANEC).

Methods

Patients with platinum-refractory extensive disease received AMR in the National Cancer Center Hospital between February 2004 and July 2012. AMR was administered 30-45 mg/m2 on days 1-3, and repeated every 3-4 weeks. The overall response rate (RR) was evaluated based on Response Evaluation Criteria in Solid Tumors (RECIST) version 1.0, progression-free survival (PFS), overall survival (OS) were estimated by the Kaplan-Meier method, and adverse events based on Common Terminology Critera for Adverse Events (CTCAE) version 4.0.

Results

Twenty-one patients received AMR. After a median eight-month follow-up, RR for 18 patients was 22.2% (95% CI, 3.0-41.4), median PFS was 3.7 months (2.6-4.8), and median OS was 7.8 months (7.2-8.4). Grade 3/4 neutropenia occurred in 52.4% of patients, and febrile neutropenia in 14.3%. Other non-hematologic toxicities were mild and no treatment-related deaths were observed.

Conclusions

AMR displays tolerable toxicity and may be feasible and effective treatment of platinum-refractory GIT-NEC/MANEC patients. Further prospective evaluation of AMR for GIT-NEC/MANEC is warranted.

Disclosure

All authors have declared no conflicts of interest.